Abstract: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (6) or a salt thereof, is prepared by reacting 2-amino-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine of formula (2) or a salt thereof, with an alkali metal nitrite in the presence of a reducing agent in an aqueous solution of an acidic compound.

Abstract: Provided are a technique for position-selectively introducing an amino group into a difluorobenzoic acid, a novel process for producing a quinolonecarboxylic acid derivative serving as an antibacterial agent, and intermediates in the production. The process comprises treating a compound represented by formula (6): with a base in a water-containing solvent.

Abstract: Taxan derivatives are produced efficiently and inexpensively, which are useful as oral-administrable antitumor compounds. A compound of formula (1) (wherein R1 is an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, an aryl group or a heterocyclic group; R2 is a hydroxyl group optionally having a protective group) is processed with an alkali metal permanganate to produce a compound of formula (2), which may be a starting material for oral-administrable antitumor compounds.

Abstract: The present invention provides a VLA-4 inhibitor having high water-solubility and excellent long-term stability; i.e., sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate.

Abstract: Provided are a technique for position-selectively introducing an amino group into a difluorobenzoic acid, a novel process for producing a quinolonecarboxylic acid derivative serving as an antibacterial agent, and intermediates in the production. The process comprises treating a compound represented by formula (6): with a base in a water-containing solvent.

Abstract: The present invention is directed to a strong platelet aggregation-inhibiting agent which does not inhibit COX-1 or COX-2. Further, the present invention provides compounds represented by formula (I), salts of the compounds, and solvates or hydrates of the compounds or the salts. Also provided are medicaments containing any of the compounds, salts, or solvates and preventive and/or therapeutic agents for ischemic diseases, containing any of the compounds, salts, or the solvates or hydrates.

Abstract: Drug compositions containing a substituted diamine compound represented by formula (1): Q1-Q2-r-N(R1)-Q3-N(R2)??(1) wherein Q3 represents the following group wherein Q5 represents an alkylene group having 4 carbon atoms, R3 represents a hydrogen atom, and R4 represents a 3-6 membered heterocyclic group which may be substituted; are useful for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Abstract: The present invention relates to diamine compounds which inhibit activated blood coagulation factor X and exhibit an anticoagulant effect and there uses for treating various diseases based on thromboembolism.

Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.

Abstract: The present invention provides intermediates needed for production of an optically active compound represented by formula (6), which enable the compound (6) to be readily synthesized in simple production steps without optical resolution, and also provides a process for producing the intermediates. A process for producing an optically active compound represented by formula (4): wherein R1 represents a protecting group for the amino group, or a salt thereof, characterized in that a reagent prepared from an titanium(IV) reagent and an alkylmetal compound is reacted with an optically active compound represented by formula (3): wherein R1 has the same meaning as defined above, if needed, in the presence of a Lewis acid.

Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.

Abstract: The invention relates a compound represented by the formula (1): Q1-Q2-C(?O)—N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents —CO— or —SO2—, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Abstract: A compound represented by formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.

Abstract: A process for producing an optically active compound represented by formula (4), or a salt thereof, wherein R1 represents a protecting group.

Abstract: 5-Methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid of formula (5) or a salt thereof, [F14] is prepared by reacting a compound of formula (6) or a salt thereof, with a trihalogenoacetyl halide in the presence of a base, followed by hydrolysis.

Abstract: A quinolone synthetic antibacterial agent and a therapeutic agent for an infection which exhibit broad spectrum and strong antibacterial activity for both Gram positive and Gram negative bacteria, and which are also highly safe are provided.

Abstract: A compound having an action of suppressing platelet aggregation is provided. This compound also exhibits excellent physical properties and oral absorbability. This compound is represented by formula (Ib): Its production method is also provided.

Abstract: By finding a novel tetrahydrofolate synthetase gene and a protein encoded by said gene, a method for identifying a compound which inhibits cell growth accelerating activity of said protein is provided, and a judging method, a preventing method and a treating method of colon cancer are provided. A DNA comprising a nucleotide sequence of from the 94th to 2934th positions of the nucleotide sequence of SEQ ID NO:1 of the SEQUENCE LISTING; a polynucleotide which specifically hybridizes with said DNA; a protein encoded by said DNA; a recombinant vector comprising said DNA; a transformant comprising said recombinant vector; an antibody for said protein; a method for producing said protein; a method for identifying a compound which inhibits cell growth accelerating activity possessed by said protein; a method for judging colon cancer, characterizing in that expressed amount of said DNA is measured; a kit for judging colon cancer; a preventive agent and/or therapeutic agent for colon cancer.

Abstract: A phospholipid derivative, utilizable for modification of liposomes and the like, which is a copolymer containing, as essential component units, a component unit A represented by the formula (1), a component unit B represented by the formula (2A) and/or the formula (2B), and a component unit C represented by the formula (3) [R1 and R2 represent hydrogen atom or methyl group, provided that R1 and R2 do not simultaneously represent methyl group; R3 represents a divalent hydrocarbon group having 1 to 3 carbon atoms; AO represents an oxyalkylene group having 2 to 4 carbon atoms; m represents an average molar number of the added oxyalkylene groups and is a number in the range represented as 4?m?100; R4 represents hydrogen atom, a hydrocarbon group or acyl group having 1 to 20 carbon atoms; R5CO and R6CO represent an acyl group having 8 to 24 carbon atoms; R7 represents a divalent hydrocarbon group having 2 to 4 carbon atoms; and X and Y represent hydrogen atom, an alkali metal atom, ammonium or an organic ammonium

Abstract: The present invention relates to a pharmaceutical solution comprising the following components (A) and (B): (A) a compound represented by the following formula (1): or a salt thereof, or a hydrate thereof; and (B) a multivalent metal compound, wherein molar ratio of the component (B) to component (A) (the multivalent compound/component (B)) is 0.01 to 0.7. A pharmaceutical solution adapted for intravascular administration containing the quinolone compound at a therapeutically sufficient amount is provided, and this solution exhibits reduced toxicity even when the multivalent metal compound were incorporated at a reduced amount.